Switch theme
Sign up to access all valuation multiples
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
2018
194
Last FY Revenue n/a
LTM EBITDA -$224M
$476M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sana Biotechnology has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$224M.
In the most recent fiscal year, Sana Biotechnology achieved revenue of n/a and an EBITDA of -$255M.
Sana Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sana Biotechnology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$224M | XXX | -$255M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$241M | XXX | -$273M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$238M | XXX | -$267M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sana Biotechnology's stock price is $2.
Sana Biotechnology has current market cap of $489M, and EV of $476M.
See Sana Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $476M | $489M | XXX | XXX | XXX | XXX | $-0.99 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sana Biotechnology has market cap of $489M and EV of $476M.
Sana Biotechnology's trades at n/a EV/Revenue multiple, and -1.9x EV/EBITDA.
Equity research analysts estimate Sana Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sana Biotechnology has a P/E ratio of -2.1x.
See valuation multiples for Sana Biotechnology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $489M | XXX | $489M | XXX | XXX | XXX |
| EV (current) | $476M | XXX | $476M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.1x | XXX | -1.9x | XXX | XXX | XXX |
| EV/EBIT | -2.0x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | -2.2x | XXX | -1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSana Biotechnology's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
Sana Biotechnology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sana Biotechnology's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sana Biotechnology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sana Biotechnology acquired XXX companies to date.
Last acquisition by Sana Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Sana Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sana Biotechnology founded? | Sana Biotechnology was founded in 2018. |
| Where is Sana Biotechnology headquartered? | Sana Biotechnology is headquartered in United States of America. |
| How many employees does Sana Biotechnology have? | As of today, Sana Biotechnology has 194 employees. |
| Who is the CEO of Sana Biotechnology? | Sana Biotechnology's CEO is Dr. Steven D. Harr, M.D.. |
| Is Sana Biotechnology publicy listed? | Yes, Sana Biotechnology is a public company listed on NAS. |
| What is the stock symbol of Sana Biotechnology? | Sana Biotechnology trades under SANA ticker. |
| When did Sana Biotechnology go public? | Sana Biotechnology went public in 2021. |
| Who are competitors of Sana Biotechnology? | Similar companies to Sana Biotechnology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sana Biotechnology? | Sana Biotechnology's current market cap is $489M |
| Is Sana Biotechnology profitable? | Yes, Sana Biotechnology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sana Biotechnology? | Sana Biotechnology's last 12 months EBITDA is -$224M. |
| What is the current EV/EBITDA multiple of Sana Biotechnology? | Current EBITDA multiple of Sana Biotechnology is -2.1x. |
| What is the current FCF of Sana Biotechnology? | Sana Biotechnology's last 12 months FCF is -$218M. |
| What is the current EV/FCF multiple of Sana Biotechnology? | Current FCF multiple of Sana Biotechnology is -2.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
